This is a multicenter, international, open-label, 2-part Phase 2 study designed to assess the efficacy and safety of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. Part 1 will consist of 2 dosing cohorts (Cohort A and Cohort B), with subjects randomized 1:1. Part 1 will be used to optimize the dosing regimen.~Part 2 will further evaluate the efficacy and safety of the selected dosing regimen.~Luveltamab tazevibulin will be administered intravenously (IV) over a 1-hour infusion time every 3 weeks.
A Phase 2 study to investigate the efficacy and safety of luveltamab tazevibulin in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.